Dementia Drugs Make the Ticker Sicker

Wilke, Allan J.
November 2009
Internal Medicine Alert;11/15/2009, Vol. 31 Issue 21, p164
Cholinesterase inhibitors place patients at risk for syncope, bradycardia, permanent pacemaker insertion, and hip fracture.


Related Articles

  • Editorial. Krapcho, A. Paul; Atta-ur-Rahman; Talaga, Patrice; Choudhary, M. Iqbal // Mini Reviews in Medicinal Chemistry;Nov2008, Vol. 8 Issue 13, p1311 

    The article discusses various reports published within the issue, including one by Andreas Hilgeroth et al on selective kinase inhibitors as potential anticancer drugs and Georg Petroianu et al on the reactivation of organic phosphorus cholinesterase inhibitors utilizing pyridinium oximes.

  • NICE turnaround on Alzheimer's. Baines, Emma // GP: General Practitioner;3/18/2005, p6 

    The article informs that National Institute for Clinical Excellence (NICE), UK government organisation, is expected to reverse its recommendation that cholinesterase inhibitors should not be given to Alzheimer's patients on the National Health Service (NHS), following criticism from a government...

  • Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. Standridge, John B. // Evidence Based Mental Health;Nov2004, Vol. 7 Issue 4, p112 

    The article presents an answer to the clinical question related to the effect of donepezil in people with mild to moderate Alzheimer's disease. The superiority, typically in cognition, of donepezil and other cholinesterase inhibitors (ChEls) to placebo has been confirmed in a systematic review....

  • Questionable recommendations for cholinesterase inhibitor use in AD.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p5 

    Discusses research being done on the use of cholinesterase inhibitors for patients with Alzheimer's disease. Reference to a study by Hanna Kaduszkiewicz and colleagues, published in the August 2005 issue of the "British Medical Journal"; Methodology of the study.

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...

  • Putting things into perspective: the nature and impact of theory of mind impairment in Huntington's disease. Eddy, Clare; Sira Mahalingappa, Sridevi; Rickards, Hugh // European Archives of Psychiatry & Clinical Neuroscience;Dec2014, Vol. 264 Issue 8, p697 

    In Huntington's disease (HD), frontostriatal dysfunction may lead to deficits in theory of mind (ToM), in addition to broader cognitive impairment. We investigated relationships between patients' spatial and social perspective taking performance and executive deficits, self-reported everyday...

  • Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice. Malone, Darren M.; Lindesay, James // Age & Ageing;May2007, Vol. 36 Issue 3, p331 

    The article focuses on a study on the use of cholinesterase inhibitor (ChEI) drug donepezil in the treatment of Alzheimer's disease (AD) in England. Syncope is said to be a common side effect of the drug. It cites the effects of the prescription of ChEIs without proper care and supervision to...

  • Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. Rainer, M.; Mucke, H. A. M.; Kr├╝ger-Rainer, C.; Kraxberger, E.; Haushofer, M.; Jellinger, K. A. // Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1327 

    Summary. In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition....

  • Efficacy and Safety of Rivastigmine in the Treatment of Behavioural and Psychological Symptoms in Chinese Dementia Patients: an Open-Label Study. Chan, C. F.; Chan, W. C.; Li, S. W. // Hong Kong Journal of Psychiatry;2006, Vol. 16 Issue 3, p101 

    Objectives: Behavioural and psychological symptoms of dementia are integral features of Alzheimer's disease. They have been recognised as important predictors for premature institutionalisation and constitute major caregiver burdens. This study examined the efficacy of rivastigmine in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics